RxDoctor Payments Data

Andrew St Martin, MD

Family Medicine · la Place, LANPI 1679521207

Payments from drug & device makers

$645in general payments, 2019–2025

Across 36 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$130
  • Johnson & Johnson$117
  • Pfizer$114
  • Dexcom, Inc.$74
  • Lilly USA, LLC$72
  • Novo Nordisk$42
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$64099%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$645 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$54,176
Medicare patients
201
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$214,910
MounjaroTirzepatide116$194,549
OzempicSemaglutide127$180,594
TrulicityDulaglutide98$152,144
JardianceEmpagliflozin53$68,299
JanuviaSitagliptin Phosphate34$55,507
XareltoRivaroxaban76$52,956
RybelsusSemaglutide31$42,400
LinzessLinaclotide36$32,075
VraylarCariprazine Hcl20$28,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$26,833
EntrestoSacubitril/Valsartan22$26,396
Breo ElliptaFluticasone/Vilanterol30$22,054
Repatha SureclickEvolocumab37$20,904
RexultiBrexpiprazole14$19,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$72$346,693214 claims
Novo NordiskOzempic, Rybelsus$42$222,994158 claims
PfizerEliquis, Premarin$114$219,406268 claims
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$15$82,77677 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$13$64,35776 claims
AbbVieLinzess, Vraylar$28$60,12856 claims
Johnson & JohnsonXarelto$117$52,95676 claims
NovartisEntresto$18$26,39622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in la Place

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →